Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Rises By 33.4%

Posted by Latisha Jones on Dec 29th, 2024

bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 177,500 shares, a growth of 33.4% from the November 30th total of 133,100 shares. Based on an average daily volume of 145,500 shares, the short-interest ratio is currently 1.2 days. Currently, 1.9% of the shares of the stock are short sold.

bioAffinity Technologies Price Performance

Shares of BIAF stock traded down $0.06 during trading hours on Friday, reaching $0.89. The company’s stock had a trading volume of 115,866 shares, compared to its average volume of 139,713. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a fifty-two week low of $0.83 and a fifty-two week high of $3.62. The company has a market capitalization of $13.87 million, a price-to-earnings ratio of -1.09 and a beta of 2.85. The firm’s 50 day simple moving average is $1.19 and its 200-day simple moving average is $1.70.

Institutional Trading of bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies at the end of the most recent quarter. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.